mutations in all and their implications for treatment decisions
Published 1 year ago • 62 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
5:14
genetic mutations in all patients & implications for treatment decisions
-
2:12
the impact of genetic abnormalities on treatment decisions in cll
-
1:07
testing for ighv and tp53 mutations to guide treatment decisions in cll
-
1:09
mitigating infection risks in patients with cll
-
1:41
the importance of integrating genomic and cytogenetic data in treatment decisions for aml
-
0:42
challenges in treating patients with ras-pathway activating mutations in all
-
2:21
the role of molecular subtyping in dlbcl and implications for treatment decisions
-
3:47
the impact of cytogenetic-risk stratification on aml outcomes
-
1:21
the prognostic impact of secondary-type mutations in patients with favorable risk aml
-
3:33
the growing role of machine learning in hematological oncology
-
1:42
applying next-generation sequencing in the diagnosis of rare inherited anemias
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
1:05
the importance of using mrd to guide treatment decisions in all
-
0:46
efficacy of diflunisal for hereditary transthyretin amyloidosis: data from the sveattr registry
-
1:50
the impact of ighv mutational status in treatment decisions in cll
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
1:37
the importance of improving treatment-free remission in patients with cml
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll